Ovarian-type epithelial tumours of the testis: immunohistochemical and molecular analysis of two serous borderline tumours of the testis

Diagnostic Pathology

Felix Bremmer²  Philipp Ströbel²  Heinz Joachim Radzun²  Stefan Schweyer¹  Peter Mayer⁴  Joachim Hansen³  Reinhard Inniger³  Hans-Ulrich Schildhaus²  Tobias Bürger² 

[1] Gemeinschaftspraxis Pathologie, Starnberg, Germany;Institute of Pathology, University Medical Center, Univeristy of Göttingen, Göttingen, Germany;Praxisgemeinschaft Pathologie, Düsseldorf/Gummersbach, Germany;Department of Urology, Catholic Clinics Oberberg, Engelskirchen, Germany

关键词: CGH;    BRAF-V600E;    KRAS;    Immunohistochemistry;    Testis;    Serous borderline tumour;   

Others  :  1220735
DOI  :  10.1186/s13000-015-0342-9

 received in 2015-03-12, accepted in 2015-06-12,  发布年份 2015

【 摘 要 】

Tumours of ovarian-epithelial type of the testis, including serous borderline tumours, represent very rare entities. They are identical to the surface epithelial tumours of the ovary and have been reported in patients from 14 to 68 years of age. We describe two cases of a 46- and a 39-year old man with incidental findings of intratesticular masses of the left respectively right testis. Under the assumption of a malignant testicular tumour the patients were subjected to inguinal orchiectomy. Histologically, the tumours were identical to their ovarian counterparts: They showed a cystic configuration with a fibrous wall and irregular papillary structures lined by partially multistratified columnar cells and areas of hobnail cells. Furthermore, there was mild cytological atypia with a proliferative activity of below 5 % as proved by Ki67 staining; mitoses could not be detected. Immunohistochemically, the tumour cells displayed expression of pan-cytokeratin AE3, progesterone receptor, Wilms’ tumour protein (WT1), and PAX8 (Paired box gene 8). Estrogen receptor was expressed in one case. Octamer-binding transcription factor-4 (OCT4), calretinin, thrombomodulin, and D2-40 were not expressed. Mutation testing of BRAF revealed a BRAF V600E mutation in one case, while testing for KRAS mutations proved to be negative in both. The BRAF mutated tumour showed strong cytosolic and membranous positivity for B-Raf also on immunohistochemical analysis. Comparative genomic hybridization of one case could not reveal any chromosomal aberrations.

【 授权许可】

   
2015 Bürger et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Ibrahim AS, Li C, Al-Jafari MS. Borderline serous papillary tumour of the testis: a case report and review of the literature. Anticancer Res. 2012; 32(11):5011-3.
• [2]Guarch R, Rivas A, Puras A, Pesce C. Papillary serous carcinoma of ovarian type of the testis with borderline differentiation. Histopathology. 2005; 46(5):588-90.
• [3]Obliers A, Hinz R, Erbersdobler A. Endometrioid borderline tumor of the testis. A rare cause of cystic neoplasia. Pathologe. 2014; 35(5):504-7.
• [4]Ulbright T, Young R. Tumors of the testis and adjacent structures. AFIP atlas of tumor pathology vol 4. Silver Spring, Maryland, American Registry of Pathology; 2013.
• [5]Schaefer IM, Schweyer S, Kuhlgatz J. Chromosomal imbalances in primary hepatic carcinosarcoma. Hum Pathol. 2012; 43(8):1328-33.
• [6]Axiotis CA. Intratesticular serous papillary cystadenoma of low malignant potential: an ultrastructural and immunohistochemical study suggesting mullerian differentiation. Am J Surg Pathol. 1988; 12(1):56-63.
• [7]Abdullah LS, Gupta R, Arnst A. Intratesticular borderline serous tumor. Int J Urol. 2006; 13(12):1536-8.
• [8]Remmele W, Kaiserling E, Zerban U, Hildebrand U, Bennek M, Jacobi-Nolde P et al.. Serous papillary cystic tumor of borderline malignancy with focal carcinoma arising in testis: case report with immunohistochemical and ultrastructural observations. Hum Pathol. 1992; 23(1):75-9.
• [9]Olla L, Di Naro N, Puliga G, Tolu GA. Intraparenchymal serous papillary cystadenoma of the testis: a case report. Pathologica. 2013; 105(1):15-7.
• [10]Michal M, Kazakov DV, Kacerovska D, Kuroda N, Lovric E, Wachter DL et al.. Paratesticular cystadenomas with ovarian stroma, metaplastic serous Mullerian epithelium, and male adnexal tumor of probable wolffian origin: A series of 5 hitherto poorly recognized testicular tumors. Ann Diagn Pathol. 2013; 17(2):151-8.
• [11]Jones S, Wang TL, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B et al.. Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol. 2012; 226(3):413-20.
• [12]Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R et al.. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010; 34(5):627-35.
• [13]Helou K, Padilla-Nash H, Wangsa D, Karlsson E, Osterberg L, Karlsson P et al.. Comparative genome hybridization reveals specific genomic imbalances during the genesis from benign through borderline to malignant ovarian tumors. Cancer Genet Cytogenet. 2006; 170(1):1-8.
• [14]Micci F, Haugom L, Ahlquist T, Andersen HK, Abeler VM, Davidson B et al.. Genomic aberrations in borderline ovarian tumors. J Transl Med. 2010; 8:21. BioMed Central Full Text
• [15]Mayr D, Kanitz V, Anderegg B, Luthardt B, Engel J, Lohrs U et al.. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Am J Clin Pathol. 2006; 126(1):101-9.
• [16]Hauptmann S, Denkert C, Koch I, Petersen S, Schluns K, Reles A et al.. Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. Hum Pathol. 2002; 33(6):632-41.
• [17]Staebler A, Heselmeyer-Haddad K, Bell K, Riopel M, Perlman E, Ried T et al.. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas. Hum Pathol. 2002; 33(1):47-59.
• [18]Wolf NG, Abdul-Karim FW, Farver C, Schrock E, du Manoir S, Schwartz S. Analysis of ovarian borderline tumors using comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer. 1999; 25(4):307-15.
• [19]Singer G, Oldt R, Cohen Y, Wang BG, Sidransky D, Kurman RJ et al.. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003; 95(6):484-6.
• [20]Bosmuller H, Fischer A, Pham DL, Fehm T, Capper D, von Deimling A et al.. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol. 2013; 44(3):329-35.
• [21]Mayr D, Hirschmann A, Lohrs U, Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol. 2006; 103(3):883-7.
• [22]Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Anglesio MS, Sharma R et al.. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. Clin Cancer Res. 2014; 20(24):6618-30.
• [23]Cundell D, Pawade J, Sohail M, Melegh Z. V600e BRAF mutation in a borderline serous tumour of the testis is genotypic evidence of similarity with phenotypic ovarian counterpart. Histopathology. 2014.